Neurological Surgery 脳神経外科49巻3号

2021年05月発行

特集 グリオーマ—現在の常識と近未来のスタンダード Ⅱグリオーマの疫学と診断

グリオーマの画像診断とradiomics

著者： 木下学¹

所属機関： ¹旭川医科大学医学部脳神経外科学講座

ページ範囲：P.501 - P.509

Point
・グリオーマ診療でCTやMRIなどの放射線画像を正しく理解するためにはある程度の基礎・理論を知っておくことが望まれる．
・定性画像と定量画像それぞれの利点と欠点，ならびに撮影条件の基本をおさえよう．
・Radiomicsなどの新規技術はこれからもますます発展すると思われるが，過度の期待は禁物である．

参考文献

1）Saito T, et al：Calcification on CT is a simple and valuable preoperative indicator of 1p/19q loss of heterozygosity in supratentorial brain tumors that are suspected grade Ⅱ and Ⅲ gliomas. Brain Tumor Pathol 33：175-182, 2016

2）Ellingson BM, et al；Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee：Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol 17：1188-1198, 2015

3）Patel SH, et al：T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas：a TCGA/TCIA project. Clin Cancer Res 23：6078-6085, 2017

4）Kinoshita M, et al：Fiber-tracking does not accurately estimate size of fiber bundle in pathological condition：initial neurosurgical experience using neuronavigation and subcortical white matter stimulation. Neuroimage 25：424-429, 2005

5）Zakhari N, et al：Prospective comparative diagnostic accuracy evaluation of dynamic contrast-enhanced（DCE）vs. dynamic susceptibility contrast（DSC）MR perfusion in differentiating tumor recurrence from radiation necrosis in treated high-grade gliomas. J Magn Reson Imaging 50：573-582, 2019

6）Law M, et al：High-grade gliomas and solitary metastases：differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 222：715-721, 2002

7）Choi C, et al：2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 18：624-629, 2012

8）Andronesi OC, et al：Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med 4：116ra4, 2012

9）Lazovic J, et al：Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. Neuro Oncol 14：1465-1472, 2012

10）Nagashima H, et al：Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma. Neuro Oncol 18：1559-1568, 2016

H-MRS in 112 hemispheric diffuse gliomas. J Magn Reson Imaging 51：1799-1809, 2020

12）Jain R, et al：“Real world” use of a highly reliable imaging sign：“T2-FLAIR mismatch” for identification of IDH mutant astrocytomas. Neuro Oncol 22：936-943, 2020

13）Broen MPG, et al：The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma：a validation study. Neuro Oncol 20：1393-1399, 2018

14）Kinoshita M, et al：T2-FLAIR mismatch sign is caused by long T1 and T2 of IDH-mutant, 1p19q non-codeleted astrocytoma. Magn Reson Med Sci 20：119-123, 2021

15）Deguchi S, et al：Clinicopathological analysis of T2-FLAIR mismatch sign in lower-grade gliomas. Sci Rep 10：10113, 2020

F-FDG dual-PET-tracer-based target delineation of malignant glioma：evaluation of its geometrical and clinical features for planning radiation therapy. J Neurosurg 131：676-686, 2019

C-methionine uptake correlates with tumor cell density rather than with microvessel density in glioma：a stereotactic image-histology comparison. Neuroimage 49：2977-2982, 2010

C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 50：1316-1322, 1998

C-methionine PET for nonenhancing gliomas. AJNR Am J Neuroradiol 37：44-50, 2016

20）Imahori Y, et al：Fluorine-18-labeled fluoroboronophenylalanine PET in patients with glioma. J Nucl Med 39：325-333, 1998

C-methionine uptake and intraoperative 5-aminolevulinic acid-induced fluorescence as separate index markers of cell density in glioma：a stereotactic image-histological analysis. Cancer 118：1619-1627, 2012

C］methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 103：498-507, 2005

23）Miyatake SI, et al：Boron neutron capture therapy for malignant brain tumors. J Neurooncol 149：1-11, 2020

24）Tatekawa H, et al：Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas. J Neurooncol 149：337-346, 2020

25）Albert NL, et al：Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol 18：1199-1208, 2016

F-fluorothymidine（FLT）PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging 35：2009-2017, 2008

F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro Oncol 14：1079-1089, 2012

F］-fluoro-ethyl-L-tyrosine PET：a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro Oncol 15：341-351, 2013

F］FLT-PET imaging does not always “light up” proliferating tumor cells. Clin Cancer Res 18：1303-1312, 2012

F-FET PET and perfusion-weighted MR imaging：a PET/MR imaging hybrid study in patients with brain tumors. J Nucl Med 55：540-545, 2014

F-FLT uptake with tumor grade and Ki-67 immunohistochemistry in patients with newly diagnosed and recurrent gliomas. J Nucl Med 53：1911-1915, 2012

F-fluorothymidine（FLT）in newly diagnosed glioma based on the 2016 WHO classification. EJNMMI Res 10：44, 2020

F-FET PET compared to contrast-enhanced MRI in glioma patients following adjuvant temozolomide chemotherapy. J Nucl Med：jnumed.120.254243, 2020

F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients. J Nucl Med 55：198-203, 2014

35）Lohmann P, et al：Predicting IDH genotype in gliomas using FET PET radiomics. Sci Rep 8：13328, 2018

F-fluoroethyl）-L-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro Oncol 17：1293-1300, 2015

C-methionine uptake decoupling score, reflects glioma cell infiltration. J Nucl Med 53：1701-1708, 2012

C-methionine positron emission tomography for reliable prediction of tumor cell density in gliomas. J Neurosurg 125：1136-1142, 2016

C-methionine PET/CT according to the 2016 WHO classification of cerebral gliomas. Eur J Nucl Med Mol Imaging 46：1678-1684, 2019

40）Arita H, et al：Lesion location implemented magnetic resonance imaging radiomics for predicting IDH and TERT promoter mutations in grade Ⅱ/Ⅲ gliomas. Sci Rep 8：11773, 2018

41）Choi YS, et al：Fully automated hybrid approach to predict the IDH mutation status of gliomas via deep learning and radiomics. Neuro Oncol 23：304-313

42）Lu CF, et al：Machine learning-based radiomics for molecular subtyping of gliomas. Clin Cancer Res 24：4429-4436, 2018

43）Fukuma R, et al：Prediction of IDH and TERT promoter mutations in low-grade glioma from magnetic resonance images using a convolutional neural network. Sci Rep 9：20311, 2019

44）Chang K, et al：Residual convolutional neural network for the determination of IDH status in low- and high-grade gliomas from MR imaging. Clin Cancer Res 24：1073-1081, 2018